2cureX and Gamidor Diagnostics have signed an agreement by which Gamidor Diagnostics becomes the distributor of IndiTreat® products in Israel. Under the terms of the collaboration, Gamidor Diagnostics will promote IndiTreat® to oncology professionals, sign supply agreements with hospitals and manage the sample logistics between the hospitals and the 2cureX labs in Copenhagen. Despite a population of just 9 million people, Israel has a particularly active pharma, biotech and medtech industry, including approximately 1,500 startups in the field.

The interaction of these companies with world-class health institutions in a limited space has produced one of the most innovative healthcare hubs in the world. Being present in this market will enhance IndiTreat® visibility, both with local and global stakeholders. The agreement has been signed for an initial term of three years, with automatic renewal for successive terms. Other terms of the agreement have not been disclosed.

Sales impact of this agreement is expected to show in 2022.